Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cimetidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 2/20 | 0.67 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | ATP4A | P20648 | 1/20 | 0.67 |
| ▸ | APEX1 | P27695 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | ATP4B | P51164 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.67 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cimetidine SCHEMBL8912417 | 1.00 | SLC47A1 (0.67) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| Cimetidine SCHEMBL11156753 | 1.00 | SLC47A1 (0.67) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| Cimetidine SCHEMBL9191182 | 1.00 | SLC47A1 (0.67) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| Cimetidine SCHEMBL9095239 | 1.00 | SLC47A1 (0.67) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| Cimetidine SCHEMBL1701195 | 0.99 | SLC47A1 (0.66) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| Cimetidine SCHEMBL10855575 | 0.99 | SLC47A1 (0.69) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| Cimetidine SCHEMBL2873984 | 0.99 | SLC47A1 (0.69) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| Cimetidine SCHEMBL10859058 | 0.99 | SLC47A1 (0.69) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| Cimetidine SCHEMBL1163516 | 0.99 | SLC47A1 (0.69) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 | |
| Cimetidine SCHEMBL2873981 | 0.99 | SLC47A1 (0.69) | SLC47A1HRH2SMN1; SMN2MEN1SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3457 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118436599-A | Cimetidine hydrochloride sustained-release suspension and preparation method and application thereof | 五邑大学 | 2024-08-06 | — | — | CN | claimed |
| EP-3988646-A1 | METHODS FOR IMPROVEMENT OF SEMEN QUALITY | University of Tennessee Research Foundation (US) | 2022-04-27 | — | — | EP | claimed |
| US-20210275531-A1 | PHOSPHODIESTERASE-5 INHIBITOR COMBINATIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | VK Research Associates Inc | 2021-09-09 | — | — | US | claimed |
| EP-3681898-A1 | METHODS AND COMPOSITIONS FOR COUPLING NUCLEIC ACID TO A FUNCTIONALIZED SUPPORT | Life Technologies AS (NO) | 2020-07-22 | — | — | EP | claimed |
| EP-1898886-B1 | NOVEL SUSTAINED RELEASE DOSAGE FORM | RUBICON RES PVT LTD (IN) | 2019-09-04 | — | — | EP | claimed |
| WO-2019048333-A1 | METHODS AND COMPOSITIONS FOR COUPLING NUCLEIC ACID TO A FUNCTIONALIZED SUPPORT | LIFE TECHNOLOGIES AS (NO) | 2019-03-14 | — | — | WO | claimed |
| WO-2017161387-A1 | COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES | REID CHRISTOPHER BRIAN (US) | 2017-09-21 | — | — | WO | claimed |
| US-9629915-B2 | Sustained release dosage form | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2017-04-25 | — | — | US | claimed |
| EP-2303241-B1 | PROCESS FOR MAKING GASTRORETENTIVE DOSAGE FORMS | UNIVERSITÉ DE LA MÉDITERRANÉE (FR) | 2015-11-04 | — | — | EP | claimed |
| CN-102872014-B | A kind of compound florfenicol composition and preparation technology thereof and application | JIUJIANG DACHENG PHARMACEUTICAL CO.,LTD. (CN) | 2015-08-19 | — | — | CN | claimed |
| EP-0746342-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD. (US) | 1996-12-11 | — | — | EP | claimed |
| US-5518730-A | Biodegradable controlled release flash flow melt-spun delivery system | FUISZ TECHNOLOGIES LTD. (US) | 1996-05-21 | — | — | US | claimed |
| EP-0746342-A4 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES LTD (US) | 1996-01-11 | — | — | EP | claimed |
| EP-0431877-B1 | Cimetidine pharmaceutical compositions | SMITHKLINE BEECHAM LAB (FR) | 1994-10-19 | — | — | EP | claimed |
| WO-1994016695-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING CIMETIDINE | SMITHKLINE BEECHAM CORPORATION (US) | 1994-08-04 | — | — | WO | claimed |
| WO-1993024154-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES, LTD. (US) | 1993-12-09 | — | — | WO | claimed |
| EP-0431877-A1 | Cimetidine pharmaceutical compositions | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1991-06-12 | — | — | EP | claimed |
| EP-0320551-A1 | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2 receptor blockers | Bristol-Myers Company (US) | 1989-06-21 | — | — | EP | claimed |
| US-4757060-A | Analgesic, H1, H2 receptor blockers | BRISTOL-MYERS COMPANY (US) | 1988-07-12 | — | — | US | claimed |
| EP-0132957-B1 | VOICE PROSTHESIS DEVICE | BIVONA, INC. (US) | 1987-10-28 | — | — | EP | claimed |